Brian Titus, who serves as vice president, controller and principal accounting officer at Corteva, executed multiple sales of Corteva, Inc. common stock on February 20, 2026, totaling 8,311 shares and generating $636,199 in gross proceeds. The trades were completed at prices between $76.5318 and $76.5652, according to a Form 4 filing with the Securities and Exchange Commission.
The timing of the transactions stands out because Corteva shares have been trading near their 52-week high of $77.98 and have delivered a roughly 25% return over the past year. The Form 4 filing also shows that Titus exercised options to acquire an additional 4,311 shares at an exercise price of $50.70 per share, representing a notional value of $218,567 tied to the option exercise.
In a separate reporting item, the filing indicates that 132 shares were disposed of at $76.31 for proceeds of $10,072. Those shares were withheld by Corteva to meet tax obligations triggered by the vesting of previously granted restricted stock units.
After accounting for the sales, option exercise and tax-withheld shares, Titus directly owns 8,089.9918 shares of Corteva common stock, as reflected in the filing.
Outside the insider transactions, publicly reported financial developments at Corteva have been mixed. The company reported fourth-quarter 2025 earnings with earnings per share of $0.22, which met expectations, while revenue came in at $3.91 billion versus forecasts of $4.24 billion, a shortfall investors have scrutinized.
Corteva has announced plans to separate its Seed and Crop Chemicals businesses later this year. That planned split has prompted analysts to flag potential execution risks. UBS, for example, has pointed to possible dissynergies and cost implications related to the separation, and subsequently downgraded its rating on the stock from Buy to Neutral while setting a price target of $80.00.
JPMorgan has taken a similar cautious stance, moving Corteva from Overweight to Neutral but raising its price target to $77.00. JPMorgan's view incorporated a sum-of-the-parts approach, applying a 13.5x multiple to the Seed business and a 10x multiple to the Crop Chemical operations in its valuation work.
Market analysis from InvestingPro included with the filing commentary indicates that Corteva appears overvalued relative to its Fair Value. The same notice points investors toward an available Pro Research Report on Corteva, one of more than 1,400 reports intended to distill detailed data into actionable research.
The package of insider activity, recent quarterly results and strategic plan to split the company has elicited a cautious response from major brokerage analysts and valuation services. Titus's sale and option exercise were disclosed in the regulatory filing process and leave him with a direct holding that market participants can monitor as corporate developments unfold.